Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-11-16Clinical Trial Update: A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder [Phase 3]
A 10-week Phase 3 trial evaluating the efficacy and safety of PD 0332334 for Generalized Anxiety Disorder has completed.
-
CLINICAL_TRIALS trial_result · 2012-11-16Clinical Trial Update: A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) [Phase 3]
A 52-week open-label safety study of PD 0332334 in subjects with Generalized Anxiety Disorder was terminated, according to the clinical tria…
-
CLINICAL_TRIALS trial_result · 2012-11-16Clinical Trial Update: A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3) [Phase 3]
Pfizer reports termination of a 10-week Phase 3 trial evaluating PD 0332334 for generalized anxiety disorder.
-
CLINICAL_TRIALS trial_result · 2012-11-16Clinical Trial Update: A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2) [Phase 3]
Pfizer's Phase 3 study of PD 0332334 in Generalized Anxiety Disorder has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-11-16Clinical Trial Update: A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) [Phase 3]
Pfizer terminated a Phase 3 trial evaluating PD 0332334 for generalized anxiety disorder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2012-10-19Clinical Trial Update: Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD) [Phase 2]
Phase 2 clinical trial update for kava kava in generalized anxiety disorder; the study has been terminated and no results are reported in th…
-
FDA approval · 2012-09-19FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
FDA approval of a supplemental application for venlafaxine from BluePoint Laboratories (ANDA).
-
FDA approval · 2012-09-19FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for venlafaxine hydrochloride from Aurobindo Pharma Limited, resulting in approval of a generic venl…
-
FDA approval · 2012-09-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride submitted by Teva Pharmaceuticals USA, Inc., resulting in changes to t…
-
FDA approval · 2012-09-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for venlafaxine hydrochloride from Aurobindo Pharma Limited.
-
FDA approval · 2012-09-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for venlafaxine hydrochloride submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2012-09-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Zydus Pharmaceuticals USA Inc.
-
CLINICAL_TRIALS research · 2012-09-19Clinical Trial Update: Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children [NA]
This clinical trial evaluates adding attentional bias modification treatment to either cognitive behavioral group therapy or a psychoeducati…
-
FDA approval · 2012-09-12FDA Approved: ESCITALOPRAM — Original Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved Jubilant Cadista Pharmaceuticals' original application for escitalopram oxalate, granting approval of a generic escitalopram pr…
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM OXALATE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves Quallent Pharmaceuticals Health LLC's original application for escitalopram oxalate as a generic antidepressant indicated for m…
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM — Original Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare Inc.'s original application for generic escitalopram, expanding availability of the antidepressant.
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM OXALATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approves Macleods Pharmaceuticals Limited's original application for escitalopram oxalate, a generic antidepressant, providing a generic…
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic escitalopram (escitalopram) under an Original Application, for its approved indications in major…
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM — Original Application (Rising Pharma Holdings, Inc.)
FDA approves an original-application ANDA for escitalopram from Rising Pharma Holdings, enabling a generic version of the antidepressant. Th…
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM OXALATE — Original Application (Exelan Pharmaceuticals Inc.)
FDA approved the original application for escitalopram oxalate as a generic product, manufactured by Exelan Pharmaceuticals Inc., to treat m…
-
FDA approval · 2012-09-11FDA Approved: ESCITALOPRAM — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for escitalopram oxalate by Aurobindo Pharma Limited, enabling a generic version of escitalopram. The …
-
FDA approval · 2012-07-31FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for venlafaxine by Alembic Pharmaceuticals Inc. to support a generic version of the antidepressant. …
-
FDA approval · 2012-07-31FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for a generic paroxetine hydrochloride product submitted by NorthStar Rx LLC.
-
FDA approval · 2012-07-31FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, authorizing its marketing as a gen…
-
CLINICAL_TRIALS trial_result · 2012-07-23Clinical Trial Update: Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy. [Phase 3]
Phase 3 randomized trial evaluating risperidone added to standard therapy versus placebo in adults with generalized anxiety disorder who res…